The generative AI drug design company dosed its first patients in a clinical trial for an AI-designed antibody, moving from concept to clinic in …
Discover more from DrWeb's Domain
Subscribe to get the latest posts sent to your email.
Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery
